What is the recommended treatment for shingles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Shingles

Start oral antiviral therapy immediately upon diagnosis, ideally within 72 hours of rash onset, with valacyclovir 1000 mg three times daily for 7 days, famciclovir 500 mg three times daily for 7 days, or acyclovir 800 mg five times daily for 7 days. 1, 2, 3

Antiviral Therapy Selection

Standard dosing regimens for immunocompetent patients:

  • Valacyclovir 1000 mg three times daily for 7 days is highly effective and resolves zoster-associated pain and postherpetic neuralgia faster than acyclovir 3
  • Valacyclovir 1.5 g twice daily for 7 days is equally safe and effective, with the advantage of improved compliance due to simpler dosing 4
  • Famciclovir 500 mg three times daily for 7 days demonstrates similar efficacy to valacyclovir 3
  • Acyclovir 800 mg five times daily for 7 days is effective but requires more frequent dosing 1, 2, 3

All antiviral medications are generally well-tolerated, with common side effects including nausea, headache, and gastrointestinal disturbances. 5

Timing of Treatment

Antiviral therapy is most effective when started within 72 hours after rash onset 1, 2, though observational data suggests valacyclovir may still provide benefit when started later than 72 hours 3. The key principle is to initiate treatment as soon as possible after symptoms appear 3.

Urgent Indications for Antiviral Therapy

Antiviral treatment is urgently indicated in:

  • All patients over 50 years of age 2
  • Herpes zoster involving the head and neck area, especially zoster ophthalmicus 2
  • Severe herpes zoster on the trunk or extremities 2
  • Immunosuppressed patients 2
  • Patients with severe atopic dermatitis or eczema 2

Relative indications exist for patients younger than 50 years with zoster on the trunk or extremities. 2

Immunocompromised Patients

For immunocompromised patients with severe disease or complications, use intravenous acyclovir 5-10 mg/kg every 8 hours until clinical resolution is achieved. 5, 6 Treatment duration may need to be prolonged beyond the standard 7 days until complete clinical resolution 6.

Pain Management

Combine appropriately dosed analgesics with a neuroactive agent (such as amitriptyline) alongside antiviral therapy to achieve painlessness. 2 This multimodal approach addresses both the acute viral infection and the neuropathic pain component.

  • Narcotics may be required for adequate pain control in patients with postherpetic neuralgia 1
  • Tricyclic antidepressants or anticonvulsants in low dosages help control neuropathic pain 1
  • Capsaicin, lidocaine patches, and nerve blocks can be used in selected patients 1

Corticosteroid Consideration

Oral corticosteroids may provide modest benefits in reducing acute zoster pain but have no essential effect on preventing postherpetic neuralgia. 2 Their use should be considered adjunctive rather than primary therapy.

Patient Education and Precautions

Advise patients that lesions are contagious to individuals who have not had chickenpox and to avoid contact with susceptible individuals until all lesions have crusted over. 5, 6

Special Considerations

Ocular involvement (zoster ophthalmicus) can lead to serious complications and generally merits referral to an ophthalmologist. 1 Valacyclovir and acyclovir demonstrate similar efficacy for controlling ocular complications 3.

Common Pitfalls

Suboptimal treatment occurs when antiviral agents are not prescribed to high-risk patients (those over 50 years) who present beyond 72 hours of rash onset. 7 In observational studies, only 50% of high-risk patients received appropriate antiviral therapy, primarily due to delayed presentation 7. Age and severity of pain are significantly associated with persistence of pain beyond 3 months, making early aggressive treatment in these populations critical 7.

References

Research

Herpes zoster guideline of the German Dermatology Society (DDG).

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2003

Guideline

Antiviral Therapy and Patient Management for Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Herpes Zoster Pain

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.